Development of a rapid and sensitive SPE-LC-MS/MS method for the simultaneous estimation of fluoxetine and olanzapine in human plasma

Biomedical Chromatography

Volumn 26, Issue 9, 2012, Pages 1077-1082

  Gopinath, Shanmugam ^a   Kumar, Ramadass Satiesh ^b   Alexander, Sekar ^b   Danabal, Palanisamy ^b  

^a Roxanne Research Laboratory Limited   (India)

^b JSS COLLEGE OF PHARMACY   (India)

Author keywords

Fluoxetine; LC MS MS; Olanzapine

Indexed keywords

DRUG PRODUCTS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PATIENT MONITORING; PHASE SEPARATION; PLASMA (HUMAN); POSITIVE IONS;

ANALYTES; FLUOXETINE; HUMAN PLASMAS; INTERNAL STANDARDS; LC-MS-MS; LC.MS/MS; OLANZAPINE; PERFORMANCE; SIMULTANEOUS ESTIMATION; SPE-LC-MS;

ELECTROSPRAY IONIZATION;

ACETONITRILE; DULOXETINE; FLUOXETINE; FORMIC ACID; GOLD; OLANZAPINE; WATER;

ACCURACY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; ELECTROSPRAY MASS SPECTROMETRY; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; PROCESS OPTIMIZATION; QUALITY CONTROL; TANDEM MASS SPECTROMETRY;

EID: 84864813550     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1750     Document Type: Article

References (17)

1. Benfield P, Heel RC and Lewis SP. Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986; 32: 481-508.
2. Bogusz MJ, Kruger KD, Maier RD, Erkwoh R and Tuchtenhagen F. Monitoring of olanzapine in serum by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry. Journal of Chromatography 1999; 732: 257-269.
3. Boulton DW, Markowitz JS and DeVane CL. A high-performance liquid chromatography assay with ultraviolet detection for olanzapine in human plasma and urine. Journal of Chromatography B 2001; 759: 319-323.
4. Catlow JT, Barton RD, Clemens M, Gillespie TA, Goodwin M and Swanson SP. Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection. Journal of Chromatography B 1995; 668: 85-90.
5. Dusci LJ, Peter Hackett L, Fellows LM and Ilett KF. Determination of olanzapine in plasma by high-performance liquid chromatography using ultraviolet absorbance detection. Journal of Chromatography B 2002; 773: 191-197.
6. FDA. Guidance for Industry. Bioanalytical Method Validation. US Department of Health and Human Services, FDA, CDER and CVM: Washington, DC, 2001. Available at: www.fda.gov/cder/guidance/index.htm.
7. Fuller RW and Snoddy HD. Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine (LY170053), an antipsychotic drug candidate. Research Communications in Chemical Pathology and Pharmacology 1992; 77: 87-93.
8. Lau YY, Selenka JM, Hanson GD, Talaat R and Ichhpurani N. Determination of pramipexole (U-98, 528) in human plasma by high-performance liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry. Journal of Chromatography B 1996; 683: 209-216.
9. Matthews JD, Bottonari KA, Polania LM, Mischoulon D, Dording CM, Irvin R and Fava M. An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses. The Journal of Clinical Psychiatry 2002; 63: 1164-1170.
10. Maya MT, Domingos CR, Guerreiro MT and Morais JA. Determination of the antidepressant fluoxetine in human plasma by LC with UV detection. Journal of Pharmaceutical and Biomedical Analysis 2000; 23: 989-996.
11. Nirogi RV, Kandikere VN, Shukla M, Mudigonda K, Maurya S, Boosi R and Yerramilli A. Development and validation of a sensitive liquid chromatography/electrospray tandem mass spectrometry assay for the quantification of olanzapine in human plasma. Journal of Pharmaceutical and Biomedical Analysis 2006; 41: 935-942.
12. Scott LJ and Perry CM. Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs 2002; 62: 507-556.
13. Shah CR, Shah NJ, Suhagia BN and Patel NM. Simultaneous assay of olanzapine and fluoxetine in tablets by column high-performance liquid chromatography and high-performance thin-layer chromatography. Journal of AOAC International 2007; 90: 1573-1578.
14. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, Buras WR, Bymaster FP, Zhang W, Spencer KA, Feldman PD and Meltzer HY. A novel augmentation strategy for treating resistant major depression. The American Journal of Psychiatry 2001; 158: 131-134.
15. Sutherland FC, Badenhorst D, de Jager AD, Scanes T, Hundt HK, Swart KJ and Hundt AF. Sensitive liquid chromatographic-tandem mass spectrometric method for the determination of fluoxetine and its primary active metabolite norfluoxetine in human plasma. Journal of Chromatography. A 2001; 914: 45-51.
16. Vlase L, Imre S and Leucuta S. Determination of fluoxetine and its N-desmethyl metabolite in human plasma by high-performance liquid chromatography. Talanta 2005; 66: 659-663.
17. Zhang JY, Fast DM, Schoenhard GL, Arora VK, Belas FJ and Blair IA. Quantitative determination of SC-68328 in dog plasma using flow injection and tandem mass spectrometry. Journal of Mass Spectrometry 2000; 35: 354-360.